ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical research"

  • Abstract Number: 1254 • 2015 ACR/ARHP Annual Meeting

    Deciphering the Immunome of Clinically Effective Immune Tolerization in Rheumatoid Arthritis

    Jing Yao Leong1,2, Raymond Ong Jr.3, Juntao Li4, Theodorus van den Broek5, Roberto Spreafico4, Maura Rossetti1 and Salvatore Albani1,2, 1SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, 2Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, 3Singhealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, 4SingHealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, 5Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA

    Background/Purpose: We have previously described (Nature Medicine, PNAS, A&R, Nature Rheum, Lancet) how oral treatment with the pro-inflammatory, heat shock protein-derived dnaJP1 peptide induces detectable…
  • Abstract Number: 1309 • 2015 ACR/ARHP Annual Meeting

    Defining an Acceptable Level of MRI Inflammation in Rheumatoid Arthritis

    Joshua Baker1, Mikkel Østergaard2, Daniel Baker3, Paul Emery4 and Philip G. Conaghan5, 1Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 3Immunology, Centocor Inc., Malvern, PA, 4Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 5University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom

    Background/Purpose: Imaging-detected inflammation persists in many rheumatoid arthritis (RA) patients despite therapy. We used data from two clinical trials of golimumab to determine thresholds for…
  • Abstract Number: 1661 • 2015 ACR/ARHP Annual Meeting

    Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine

    Emmanuel Monnet1, Limin Shang1, Geneviève Lapeyre1, Kathy De Graaf2, Eric Hatterer1, Gaelle Wambiekele1, Walter Ferlin1, Philippe Jacqmin3, Cem Gabay4, Jeremy Sokolove5, Simon Jones6, Ernest H. Choy7, Iain B. McInnes8, Marie Kosco-Vilbois1 and Cristina De Min1, 1NovImmune S.A., Geneva, Switzerland, 2Novimmune S.A., Geneva, Switzerland, 3SGS Exprimo, Mechelen, Belgium, 4Rheumatology, Geneva University Hospital, Geneva, Switzerland, 5Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 6Cardiff Institute of Infection & Immunity, Cardiff, United Kingdom, 7Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, 8Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Innate immunity is implicated in RA pathogenesis and is likely mediated via TLR pathways, with anti-citrullinated protein antibodies (ACPA) serving as key triggers. NI-0101…
  • Abstract Number: 1664 • 2015 ACR/ARHP Annual Meeting

    Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.

    Jose L. Pablos1, Navarro Sarabia F2, Francisco J. Blanco3, Jose Andres Roman Ivorra4, Alberto Alonso5, Emilio Martin-Mola6 and Miguel Cantalejo-Moreira7, 1Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, 2Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, 3Cartilage Biology Group. Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, 4Rheumatology, H.U. P. La Fe, Valencia, Spain, 5H Cruces, Baracaldo, Spain, 6H La Paz, Madrid, Spain, 7Rheumatology Unit, Hospital de Fuenlabrada, Fuenlabrada, Spain

    Background/Purpose: Tocilizumab (TCZ) represents an efficacious alternative for patients with rheumatoid arthritis (RA) with an inadequate clinical response to biological or non-biological disease-modifying anrirheumatic drugs…
  • Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting

    A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

    Alexandra Steinberg1, Harinder Chera1, Yun-Jung Choi1, Robert Martin1, Charles McWherter1, Yunbin Zhang2, Pol Boudes1 and on behalf of the Arhalofenate Anti-Flare Therapy Study Group, 1Cymabay Therapeutics, Newark, CA, 2INC Research, Raleigh, NC

    Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout.  It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…
  • Abstract Number: 2302 • 2015 ACR/ARHP Annual Meeting

    The Impact of Prior Fibromyalgia Treatment on the Response to Pregabalin in Fibromyalgia Clinical Trials

    Lynne Pauer1, Andrew Clair2, Pritha Bhadra Brown2, Marie Ortiz2 and Joseph Scavone1, 1Pfizer Inc, Groton, CT, 2Pfizer Inc., New York, NY

    Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder for which Lyrica is an approved treatment. Antidepressants, gabapentin, muscle relaxants, and opioids are frequently used…
  • Abstract Number: 2440 • 2015 ACR/ARHP Annual Meeting

    Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis

    Jaime Guzman1, Andrew Henrey2, Thomas Loughin2, Roberta Berard3, Natalie Shiff4, Roman Jurencak5, Susanne Benseler6, Lori B. Tucker7 and ReACCh-Out Investigators, 1Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, 2Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, 3Children's Hospital of Western Ontario, London, ON, Canada, 4Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, 5University of Ottawa, Ottawa, ON, Canada, 6Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, 7Rheumatology, BC Children's Hospital, Vancouver, BC, Canada

    Background/Purpose: To define distinct disease course groups among children with Juvenile Idiopathic Arthritis (JIA) based on observed changes in quality of life, pain, medication requirements,…
  • Abstract Number: 2754 • 2015 ACR/ARHP Annual Meeting

    Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of BI 655064, an Antagonistic Anti-CD40 Antibody Following Single-Dose Administration in Chinese and Japanese Healthy Volunteers

    Jiyoon Kim1, Yasuhiro Tsuda2, Kazuhiko Yamamoto3, Ralf Thiedmann4, Corinna Schoelch4, Stephen Norris5, Steven Padula6, Juergen Steffgen4 and In-Jin Jang7, 1Boehringer Ingelheim Korea Ltd., Seoul, South Korea, 2Clinical PK/PD department, Nippon Boehringer-Ingelheim.Co.,Ltd., Kobe, Japan, 3Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 5Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, 7Seoul National University Hospital, Seoul, South Korea

    Background/Purpose: The CD40-CD40L pathway may play a major role in autoimmune disorders like rheumatoid arthritis or SLE. Blocking this pathway may be a promising new…
  • Abstract Number: 3145 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Modified-Release Prednisone in Patients with Polymyalgia Rheumatica: Results of a Multicenter, Randomized, Active-Controlled Phase 3 Study

    Maurizio Cutolo1, Michael Hopp2, Stefan Liebscher2, Bhaskar Dasgupta3 and Frank Buttgereit4, 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, 2Medical Science, Mundipharma Research GmbH & Co. KG, Limburg, Germany, 3Rheumatology, Southend University Hospital, Essex, United Kingdom, 4Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by persisting proximal pain and morning stiffness of the neck, shoulder and hip girdles of 2 weeks' duration, an…
  • Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting

    In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression

    Karen Hambardzumyan1, R.J. Bolce2, Saedis Saevarsdottir*3, Kristina Forslind4, Ingemar F. Petersson5, Pierre Geborek6, Eric H. Sasso2, David Chernoff2, Scott Cruickshank7 and Ronald F. van Vollenhoven8, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Sweden, 5Lund University, Lund, Sweden, 6Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 7Scott Cruickshank and Associates, Inc., Santa Barbara, CA, 8Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden

    Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
  • Abstract Number: 259 • 2014 ACR/ARHP Annual Meeting

    Development of Pediatric Item Banks to Measure Pain Behavior in the Patient Reported Outcomes Measurement Information System

    Esi M. Morgan DeWitt1, Kimberly Barnett2, Wen-Hung Chen3, Jennifer Farrell4, Dennis Revicki5, Adam Carle6, Karon Cook7, Kenneth Goldschneider8, Carlton Dampier9, David D. Sherry10 and Susmita Kashikar-Zuck2, 1Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Evidera, Bethesda, MD, 4Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Outcomes Research, Evidera, Bethesda, MD, 6Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Center for Patient-Centered Outcomes - Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 8Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, 10Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose The NIH Patient Reported Outcomes Measurement Information System (PROMIS) has created publicly available patient reported outcomes measures in several domains of physical, social and…
  • Abstract Number: L15 • 2014 ACR/ARHP Annual Meeting

    Remission Induction By Etanercept in Enthesitis Related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)

    Ivan Foeldvari1, Gerd Horneff2, Kirsten Minden3, Ralf Trauzeddel4, J B. Kuemmerle-Deschner5, Klaus Tenbrock6, Gerd Ganser7 and Hans-Iko Huppertz8, 1Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, 2Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 3Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, 4Pediatrics, Helios Clinics, Berlin, Germany, 5Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, 6University Aachen, Aachen, Germany, 7Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, 8Kinderklinik, Krinikum Bremen-Mitte, Bremen, Germany

    Background/Purpose: Enthesitis related arthritis (ERA) is a Juvenile Idiopathic Arthritis category, clinically related to the syndrome of undifferentiated spondyloarthropathy in adults. This study is intended…
  • Abstract Number: 2230 • 2014 ACR/ARHP Annual Meeting

    Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials

    Morten Asser Karsdal1, Anne C. Bay-Jensen2, Asger Bihlet3, Peter Alexandersen4, Inger Byrjalsen3, Jeppe Andersen3, Bente J. Riis3 and Claus Christiansen3, 1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark, 4Center for Clinical and Basic Research, Vejle, Denmark

    Background/Purpose: To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a…
  • Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting

    Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

    Philip J. Mease1, Roy Fleischmann2, Owen Davies3, Tommi Nurminen4 and Désirée van der Heijde5, 1Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, 2Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, 3UCB Pharma, Slough, United Kingdom, 4UCB Pharma, Monheim, Germany, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…
  • Abstract Number: 1505 • 2014 ACR/ARHP Annual Meeting

    The Biosimilar Landscape: A Systematic Review of Its Current Status

    Niti Goel1,2 and Kamali Chance3, 1Rheumatology Center of Excellence, Quintiles, Durham, NC, 2Duke University Medical Center, Durham, NC, 3Global Biosimilars Unit, Quintiles, Durham, NC

    Background/Purpose In the last 5 years, the number of biosimilars in development for the treatment of immunologic diseases has increased as innovator etanercept (ETA), infliximab (IFX), adalimumab…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology